EyePoint Pharmaceuticals Inc PV3B
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PV3B is a good fit for your portfolio.
News
-
EyePoint Pharmaceuticals' stock plunges as eye treatment fails to meet trial goal
-
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
-
EyePoint announces $175 million stock offering following record surge in share price
-
EyePoint Pharmaceuticals' stock soars 200% after company announces positive data for macular degeneration treatment
Trading Information
- Previous Close Price
- €8.58
- Day Range
- €8.64–8.64
- 52-Week Range
- €2.06–27.60
- Bid/Ask
- €8.67 / €8.93
- Market Cap
- €450.01 Mil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 7.96
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 144
- Website
- https://www.eyepointpharma.com
Comparables
Valuation
|
Metric
|
PV3B
|
EWTX
|
TARS
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.85 | 3.05 | 4.25 |
Price/Sales | 7.96 | — | 22.95 |
Price/Cash Flow | — | — | — |
Price/Earnings
PV3B
EWTX
TARS
Financial Strength
|
Metric
|
PV3B
|
EWTX
|
TARS
|
|---|---|---|---|
Quick Ratio | 4.83 | 36.49 | 7.76 |
Current Ratio | 5.08 | 37.08 | 8.01 |
Interest Coverage | −202.71 | — | −43.93 |
Quick Ratio
PV3B
EWTX
TARS
Profitability
|
Metric
|
PV3B
|
EWTX
|
TARS
|
|---|---|---|---|
Return on Assets (Normalized) | −25.84% | −23.18% | −49.27% |
Return on Equity (Normalized) | −42.72% | −24.45% | −62.79% |
Return on Invested Capital (Normalized) | −44.04% | −28.92% | −58.38% |
Return on Assets
PV3B
EWTX
TARS
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Mlzxpvlg | Jdvsmnh | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Gxgdcsmt | Bkcys | $114.2 Bil | |||
| Moderna Inc
MRNA
| Thwlldd | Tcd | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Tcbxghfb | Fxb | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Tgrrqjmdm | Rwmc | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mcgngkft | Zrflgbj | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Cqzmbpj | Qzgnptk | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Wgdsccxq | Nqck | $12.8 Bil | |||
| Incyte Corp
INCY
| Hsmftfcgv | Zvhpf | $12.2 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Vjbxmjqj | Wjbgx | $12.2 Bil |